Genmab A/S
AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT

Last updated:

Abstract:

The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.

Status:
Application
Type:

Utility

Filling date:

10 Apr 2019

Issue date:

11 Mar 2021